Sanjay K Murthy

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/2456156/sanjay-k-murthy-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

44	507	13	22
papers	citations	h-index	g-index
49	876 ext. citations	3.3	3.78
ext. papers		avg, IF	L-index

#	Paper	IF	Citations
44	Providing Hospitalized Ulcerative Colitis Patients With Practice Guidelines Improves Patient-Reported Outcomes. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021 , 4, 131-136	0.5	O
43	Multivariable models for advanced colorectal neoplasms in screen-eligible individuals at low-to-moderate risk of colorectal cancer: towards improving colonoscopy prioritization. <i>BMC Gastroenterology</i> , 2021 , 21, 383	3	
42	Trends in Corticosteroid Use During the Era of Biologic Therapy: A Population-Based Analysis. <i>American Journal of Gastroenterology</i> , 2021 , 116, 1284-1293	0.7	2
41	Shifting health care use from hospitalizations and surgeries to outpatient visits in children with inflammatory bowel disease: a population-based cohort study from Ontario, Canada. <i>Journal of Crohnwand Colitis</i> , 2021 ,	1.5	1
40	Surgery and the Subtype of Inflammatory Bowel Disease Impact the Risk of Venous Thromboembolism After Hospital Discharge. <i>Digestive Diseases and Sciences</i> , 2021 , 1	4	3
39	Home parenteral nutrition patients on mixed oil lipid emulsion have a higher rate of hospitalizations compare to those on soybean oil- a prospective 2-year cohort study. <i>Clinical Nutrition</i> , 2021 , 40, 4616-4623	5.9	0
38	Variation in care of patients with elderly-onset inflammatory bowel disease in Ontario, Canada: A population-based cohort study. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021 , 4, e16-e3	6 0.5	O
37	CrohnWand Colitis CanadaW2021 Impact of COVID-19 & Inflammatory Bowel Disease in Canada: A Knowledge Translation Strategy. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021 , 4, S10-S	:19 ⁵	
36	CrohnWand Colitis CanadaW2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Seniors With IBD. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021 , 4, S34-S39	0.5	
35	CrohnWand Colitis CanadaW2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Epidemiology-The Trends of Disease Over Time. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021 , 4, S20-S26	0.5	
34	CrohnWand Colitis CanadaW2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Risk Factors and Medications. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021 , 4, S40-S45	0.5	1
33	CrohnWand Colitis CanadaW2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Health Care Delivery During the Pandemic and the Future Model of Inflammatory Bowel Disease Care. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021 , 4, S61-S67	0.5	0
32	CrohnWand Colitis CanadaW2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Executive Summary. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021 , 4, S1-S9	0.5	O
31	CrohnWand Colitis CanadaW2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Children and Expectant Mothers With Inflammatory Bowel Disease. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021 , 4, S27-S33	0.5	О
30	CrohnWand Colitis CanadaW2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: COVID-19 Vaccines-Biology, Current Evidence and Recommendations. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021 , 4, S54-S60	0.5	O
29	AGA Clinical Practice Update on Endoscopic Surveillance and Management of Colorectal Dysplasia in Inflammatory Bowel Diseases: Expert Review. <i>Gastroenterology</i> , 2021 , 161, 1043-1051.e4	13.3	6
28	Venous thromboembolic events in inflammatory bowel diseases: A review of current evidence and guidance on risk in the post-hospitalization setting. <i>Thrombosis Research</i> , 2020 , 194, 26-32	8.2	3

Combined Biologic and Immunomodulatory Therapy is Superior to Monotherapy for Decreasing the 27 Risk of Inflammatory Bowel Disease-Related Complications. *Journal of Crohnward Colitis*, **2020**, 14, 1354-7363 Risk of Venous Thromboembolism After Hospital Discharge in Patients With Inflammatory Bowel 26 4.5 20 Disease: A Population-based Study. Inflammatory Bowel Diseases, 2020, 26, 1761-1768 Vedolizumab treatment across antiretroviral treatment interruption in chronic HIV infection: the HAVARTI protocol for a pilot dose-ranging clinical trial to assess safety, tolerance, immunological 25 3 and virological activity. BMJ Open, 2020, 10, e041359 Longitudinal Trends in the Direct Costs and Health Care Utilization Ascribable to Inflammatory Bowel Disease in the Biologic Era: Results From a Canadian Population-Based Analysis. American 24 0.7 14 Journal of Gastroenterology, 2020, 115, 128-137 Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study. 23 19.2 74 Gut, 2020, 69, 274-282 Absence of Day 3 Steroid Response Predicts Colitis-Related Complications and Colectomy in Hospitalized Ulcerative Colitis Patients. Journal of the Canadian Association of Gastroenterology, 22 0.5 2 **2020**, 3, 169-176 Tumor Necrosis Factor Inhibitors May Have Limited Efficacy for Complex Perianal Fistulas Without 21 O 4 Luminal Crohn&Disease. Digestive Diseases and Sciences, 2020, 65, 1784-1789 Predictive models of disease burden at diagnosis in persons with adult-onset ulcerative colitis using 20 health administrative data. BMC Gastroenterology, 2019, 19, 13 The Effect of Initiation of Anti-TNF Therapy on the Subsequent Direct Health Care Costs of 19 4.5 15 Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2019, 25, 1718-1728 The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services 18 0.5 31 Utilization. Journal of the Canadian Association of Gastroenterology, 2019, 2, S17-S33 Health Care Utilization and Costs for Patients With End-Stage Liver Disease Are Significantly Higher at the End of Life Compared to Those of Other Decedents. Clinical Gastroenterology and Hepatology 17 6.9 10 , 2019, 17, 2339-2346.e1 Past and Future Burden of Inflammatory Bowel Diseases Based on Modeling of Population-Based 16 13.3 132 Data. Gastroenterology, **2019**, 156, 1345-1353.e4 Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related 6.9 15 15 Complications in a Population-based Cohort Study. Clinical Gastroenterology and Hepatology, 2019, Clinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohn&Disease: The 14 4.5 34 Toronto Consensus. Inflammatory Bowel Diseases, 2019, 25, 1-13 Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of 8 6.9 13 Luminal Crohn&Disease. Clinical Gastroenterology and Hepatology, 2019, 17, 1680-1713 Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of 12 0.5 14 Luminal Crohn W Disease. Journal of the Canadian Association of Gastroenterology, 2019, 2, e1-e34 The Impact of Clostridium difficile Infection on Mortality in Patients With Inflammatory Bowel 11 17 Disease: A Systematic Review and Meta-Analysis. Journal of Clinical Gastroenterology, 2019, 53, 127-133 ³ Appropriateness of Biologics in the Management of CrohnWDisease Using RAND/UCLA 10 Appropriateness Methodology. Inflammatory Bowel Diseases, 2019, 25, 328-335

9	Temporal trends in postcolonoscopy colorectal cancer rates in 150- to 74-year-old persons: a population-based study. <i>Gastrointestinal Endoscopy</i> , 2018 , 87, 1324-1334.e4	5.2	12	
8	Variable Endoscopist performance in proximal and distal adenoma detection during colonoscopy: a retrospective cohort study. <i>BMC Gastroenterology</i> , 2018 , 18, 73	3	3	
7	Rural and urban disparities in the care of Canadian patients with inflammatory bowel disease: a population-based study. <i>Clinical Epidemiology</i> , 2018 , 10, 1613-1626	5.9	19	
6	Clinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohn&Disease: The Toronto Consensus. <i>Journal of the Canadian Association of Gastroenterology</i> , 2018 , 1, 141-154	0.5	4	
5	High end of life health care costs and hospitalization burden in inflammatory bowel disease patients: A population-based study. <i>PLoS ONE</i> , 2017 , 12, e0177211	3.7	8	
4	Perspectives on endoscopic surveillance of dysplasia in inflammatory bowel disease: a survey of academic gastroenterologists. <i>Endoscopy International Open</i> , 2017 , 5, E974-E979	3	11	
3	An Unusual Skin Manifestation in a Patient With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, A35-6	6.9	2	
2	Increased Risk of Venous Thromboembolic Events With Corticosteroid Versus Biologic Therapy for Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 166-7	6.9	1	
1	Extent of Early Clinical Response to Infliximab Predicts Long-term Treatment Success in Active Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2015 , 21, 2090-6	4.5	19	